Efficacy and safety of retreatment regimen of sofosbuvir with ombitasvir/paritaprevir/ritonavir plus ribavirin in patients with HCV genotype 4 infection

Trial Profile

Efficacy and safety of retreatment regimen of sofosbuvir with ombitasvir/paritaprevir/ritonavir plus ribavirin in patients with HCV genotype 4 infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 New trial record
    • 15 Mar 2018 Retreatment efficacy and safety results were published in the Digestive Diseases and Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top